Zhe-Yi Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhe-Yi Hu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Robert B. Parker
University of Tennessee Health Science Center, College of Pharmacy Department of Clinical Pharmacy Memphis TN 38163 USA
3 shared publicationsS. Casey Laizure
University of Tennessee Health Science Center, College of Pharmacy Department of Clinical Pharmacy Memphis TN 38163 USA
3 shared publicationsVanessa L. Herring
University of Tennessee Health Science Center, College of Pharmacy Department of Clinical Pharmacy Memphis TN 38163 USA
3 shared publications- Bernd Meibohm
Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center
1 shared publication - Bradley A. Boucher
Department of Clinical Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163-0001, USA
1 shared publication Dandan Tian
1 shared publication
Latest Publications
- 9 August 2015
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 41 (6) , 689-703
A Physiologically Based Pharmacokinetic Model of Amiodarone and its Metabolite Desethylamiodarone in Rats: Pooled Analysis of Published Data
Amiodarone (AMD) is one of the most effective drugs for rhythm control of atrial fibrillation. The use of AMD is also associated with adverse effects in multiple tissues. Both the parent compound and its major metabolite desethylamiodarone (DEA) contribute to the drug’s therapeutic and toxic action. The present study aimed to build a whole-body physiologically based pharmacokinetic (PBPK) model for AMD and DEA in rats. Pharmacokinetic data from multiple studies were collected. Some of the data were pooled together to develop the PBPK model; others were used to evaluate the model. Development of the model also involved in vitro to in vivo extrapolation based on in vitro metabolism data. The final model consisted of 11 tissue compartments, including therapeutic target organs and those to which AMD and DEA may be harmful. Model simulations were in good agreement with the observed time courses of the drug–metabolite pair in tissues, under various dosing scenarios. The key pharmacokinetic properties of AMD, such as extensive tissue distribution, substantial storage in the fat tissue, and long half-lives in many tissues, were closely reflected. The developed PBPK model can be regarded as the first step towards a PBPK–pharmacodynamic model that can used to mechanistically evaluate and explain the high adverse event rate and potentially to determine which factors are the primary drives for experiencing an adverse event.
- 9 August 2015
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 41 (6) , 689-703
A Physiologically Based Pharmacokinetic Model of Amiodarone and its Metabolite Desethylamiodarone in Rats: Pooled Analysis of Published Data
Amiodarone (AMD) is one of the most effective drugs for rhythm control of atrial fibrillation. The use of AMD is also associated with adverse effects in multiple tissues. Both the parent compound and its major metabolite desethylamiodarone (DEA) contribute to the drug’s therapeutic and toxic action. The present study aimed to build a whole-body physiologically based pharmacokinetic (PBPK) model for AMD and DEA in rats. Pharmacokinetic data from multiple studies were collected. Some of the data were pooled together to develop the PBPK model; others were used to evaluate the model. Development of the model also involved in vitro to in vivo extrapolation based on in vitro metabolism data. The final model consisted of 11 tissue compartments, including therapeutic target organs and those to which AMD and DEA may be harmful. Model simulations were in good agreement with the observed time courses of the drug–metabolite pair in tissues, under various dosing scenarios. The key pharmacokinetic properties of AMD, such as extensive tissue distribution, substantial storage in the fat tissue, and long half-lives in many tissues, were closely reflected. The developed PBPK model can be regarded as the first step towards a PBPK–pharmacodynamic model that can used to mechanistically evaluate and explain the high adverse event rate and potentially to determine which factors are the primary drives for experiencing an adverse event.
- 25 February 2015
- Published by Bentham Science Publishers Ltd. in Current Drug Metabolism
- Vol. 15 (8) , 808-817
CYP3A4-mediated Pharmacokinetic Interactions in Cancer Therapy
Cytochromes P450 enzymes, especially CYP3A4, are responsible for metabolizing a broad range of anticancer drugs. Combination therapy is common in patients with cancer, which may cause potential drug drug interactions (DDIs) leading to increased risk of side-effects/toxicity or decreased effectiveness. The review summarizes CYP3A4-mediated DDIs, with anticancer drugs as CYP3A4 substrates or modulators, in clinical trials during cancer therapy and aims to increase clinicians' awareness to take caution to reduce the risk.
- 25 February 2015
- Published by Bentham Science Publishers Ltd. in Current Drug Metabolism
- Vol. 15 (8) , 808-817
CYP3A4-mediated Pharmacokinetic Interactions in Cancer Therapy
Cytochromes P450 enzymes, especially CYP3A4, are responsible for metabolizing a broad range of anticancer drugs. Combination therapy is common in patients with cancer, which may cause potential drug drug interactions (DDIs) leading to increased risk of side-effects/toxicity or decreased effectiveness. The review summarizes CYP3A4-mediated DDIs, with anticancer drugs as CYP3A4 substrates or modulators, in clinical trials during cancer therapy and aims to increase clinicians' awareness to take caution to reduce the risk.
- 25 February 2015
- Published by Bentham Science Publishers Ltd. in Current Drug Metabolism
- Vol. 15 (8) , 759-760
Editorial (Thematic Issue: Study and Prediction of Pharmacokinetic Drug-Drug Interactions)
- 25 February 2015
- Published by Bentham Science Publishers Ltd. in Current Drug Metabolism
- Vol. 15 (8) , 759-760
Editorial (Thematic Issue: Study and Prediction of Pharmacokinetic Drug-Drug Interactions)
- 20 April 2014
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 28 (11) , 1285-1292
Identification of alcohol‐dependent clopidogrel metabolites using conventional liquid chromatography/triple quadrupole mass spectrometry
RATIONALE: Clopidogrel (CLO) is a prodrug used to prevent ischemic events in patients undergoing percutaneous coronary intervention or with myocardial infarction. A previous study found ethyl clopidogrel (ECLO) is formed by transesterification of CLO when incubated with alcohol in human liver microsomes. We hypothesize that ECLO will be subject to further metabolism and developed an assay to identify its metabolites. METHODS: A liquid chromatography/triple quadrupole mass spectrometry (LC/MS/MS) method was developed to identify metabolites of ECLO. According to the predicted metabolic pathway of ECLO, precursor–product ion pairs were used to screen the possible metabolites of ECLO in human liver S9 fractions. Subsequently, the detected metabolites were characterized by the results of product ion scan. RESULTS: In the presence of alcohol, CLO was tranesterified to ECLO, which was further oxidized to form ethylated 2‐oxo‐clopidogrel and several ethylated thiol metabolites including the ethylated form of the H4 active metabolite. CONCLUSIONS: The ECLO formed by transesterification with alcohol is subject to metabolism by CYP450 enzymes producing ethylated forms of 2‐oxo‐clopidogrel and the active H4 thiol metabolite. Copyright © 2014 John Wiley & Sons, Ltd.
- 20 April 2014
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 28 (11) , 1285-1292
Identification of alcohol‐dependent clopidogrel metabolites using conventional liquid chromatography/triple quadrupole mass spectrometry
RATIONALE: Clopidogrel (CLO) is a prodrug used to prevent ischemic events in patients undergoing percutaneous coronary intervention or with myocardial infarction. A previous study found ethyl clopidogrel (ECLO) is formed by transesterification of CLO when incubated with alcohol in human liver microsomes. We hypothesize that ECLO will be subject to further metabolism and developed an assay to identify its metabolites. METHODS: A liquid chromatography/triple quadrupole mass spectrometry (LC/MS/MS) method was developed to identify metabolites of ECLO. According to the predicted metabolic pathway of ECLO, precursor–product ion pairs were used to screen the possible metabolites of ECLO in human liver S9 fractions. Subsequently, the detected metabolites were characterized by the results of product ion scan. RESULTS: In the presence of alcohol, CLO was tranesterified to ECLO, which was further oxidized to form ethylated 2‐oxo‐clopidogrel and several ethylated thiol metabolites including the ethylated form of the H4 active metabolite. CONCLUSIONS: The ECLO formed by transesterification with alcohol is subject to metabolism by CYP450 enzymes producing ethylated forms of 2‐oxo‐clopidogrel and the active H4 thiol metabolite. Copyright © 2014 John Wiley & Sons, Ltd.
- 24 January 2014
- Published by Wiley in British Journal of Pharmacology
- Vol. 171 (4) , 1043-1053
Physiologically based pharmacokinetic modelling andin vivo[I]/Kiaccurately predictP‐glycoprotein‐mediated drug‐drug interactions with dabigatran etexilate
Background and purpose: In vitroinhibitory potency (Ki)‐based predictions ofP‐glycoprotein (P‐gp)‐mediated drug‐drug interactions (DDIs) are hampered by the substantial variability in inhibitory potency. In this study,in vivo‐based [I]/Kivalues were used to predict theDDIrisks of aP‐gp substrate dabigatran etexilate (DABE) using physiologically based pharmacokinetic (PBPK) modelling.Experimental approach: A baselinePBPKmodel was established with digoxin, a knownP‐gp substrate. TheKm(P‐gp transport) of digoxin in the baselinePBPKmodel was adjusted toKmito fit the change of digoxin pharmacokinetics in the presence of aP‐gp inhibitor. Then ‘in vivo’ [I]/Kiof thisP‐gp inhibitor was calculated usingKmi/Km. BaselinePBPKmodel was developed forDABE, and the ‘in vivo’ [I]/Kiwas incorporated into this model to simulate the static effect ofP‐gp inhibitor onDABEpharmacokinetics. This approach was verified by comparing the observed and the simulatedDABEpharmacokinetics in the presence of five differentP‐gp inhibitors.Key results: This approach accurately predicted the effects of fiveP‐gp inhibitors onDABEpharmacokinetics (98–133% and 89–104% for the ratios ofAUCandCmaxrespectively). The effects of 16 otherP‐gp inhibitors on the pharmacokinetics ofDABEwere also confidently simulated.Conclusions and implications: ‘In vivo’ [I]/KiandPBPKmodelling, used in combination, can accurately predictP‐gp‐mediatedDDIs. The described framework provides a mechanistic basis for the proper design of clinical DDI studies, as well as avoiding unnecessary clinicalDDIstudies.
- 24 January 2014
- Published by Wiley in British Journal of Pharmacology
- Vol. 171 (4) , 1043-1053
Physiologically based pharmacokinetic modelling andin vivo[I]/Kiaccurately predictP‐glycoprotein‐mediated drug‐drug interactions with dabigatran etexilate
Background and purpose: In vitroinhibitory potency (Ki)‐based predictions ofP‐glycoprotein (P‐gp)‐mediated drug‐drug interactions (DDIs) are hampered by the substantial variability in inhibitory potency. In this study,in vivo‐based [I]/Kivalues were used to predict theDDIrisks of aP‐gp substrate dabigatran etexilate (DABE) using physiologically based pharmacokinetic (PBPK) modelling.Experimental approach: A baselinePBPKmodel was established with digoxin, a knownP‐gp substrate. TheKm(P‐gp transport) of digoxin in the baselinePBPKmodel was adjusted toKmito fit the change of digoxin pharmacokinetics in the presence of aP‐gp inhibitor. Then ‘in vivo’ [I]/Kiof thisP‐gp inhibitor was calculated usingKmi/Km. BaselinePBPKmodel was developed forDABE, and the ‘in vivo’ [I]/Kiwas incorporated into this model to simulate the static effect ofP‐gp inhibitor onDABEpharmacokinetics. This approach was verified by comparing the observed and the simulatedDABEpharmacokinetics in the presence of five differentP‐gp inhibitors.Key results: This approach accurately predicted the effects of fiveP‐gp inhibitors onDABEpharmacokinetics (98–133% and 89–104% for the ratios ofAUCandCmaxrespectively). The effects of 16 otherP‐gp inhibitors on the pharmacokinetics ofDABEwere also confidently simulated.Conclusions and implications: ‘In vivo’ [I]/KiandPBPKmodelling, used in combination, can accurately predictP‐gp‐mediatedDDIs. The described framework provides a mechanistic basis for the proper design of clinical DDI studies, as well as avoiding unnecessary clinicalDDIstudies.
- Open Access
- 10 July 2013
- Published by Wiley in Journal of Mass Spectrometry
- Vol. 48 (8) , 945-950
Nonvolatile salt‐free stabilizer for the quantification of polar imipenem and cilastatin in human plasma using hydrophilic interaction chromatography/quadrupole mass spectrometry with contamination sensitive off‐axis electrospray
A hydrophilic interaction chromatography/mass spectrometry (HILIC‐MS)‐based assay for imipenem (IMP) and cilastatin (CIL) was recently reported. This orthogonal electrospray ion source‐based (ORS) assay utilized nonvolatile salt (unremovable) to stabilize IMI in plasma. Unfortunately, this method was not applicable to conventional MS with off‐axis spray (OAS‐MS) because MS sensitivity was rapidly deteriorated by the nonvolatile salt. Therefore, we aimed to find a nonvolatile salt‐ and ion suppression‐free approach to stabilize and measure the analytes in plasma using OAS‐MS. Acetonitrile and methanol were tested to stabilize the analytes in the plasma samples. The recoveries, matrix effects and stabilities of the analytes in the stabilizer‐treated samples were studied. The variations in MS signal intensities were used as the indicator of the assay ruggedness. The results show that a mixture of methanol and acetonitrile (1:1) is best for the storage and measurement of IMP and CIL in human plasma. Utilization of this precipitant not only blocked the hydrolysis of the analytes in plasma but also resulted in an ion suppression‐free, fast (120 s per sample) and sensitive detection. The sensitivity obtained using the less sensitive OAS‐MS (API3000, 4 pg on column) is much greater than that of the published ORS‐MS‐based assay (API4000, 77 pg on column). The ruggedness of the assay was demonstrated by its constant MS signal intensity. In conclusion, an improved HILIC/MS‐based assay for IMP and CIL was established. The approach presented here provides a simple solution to the challenge of analyzing hydrolytically unstable β‐lactam antibiotics in biological samples. Copyright © 2013 John Wiley & Sons, Ltd.
- 10 July 2013
- Published by Wiley in Journal of Mass Spectrometry
- Vol. 48 (8) , 945-950
Open AccessNonvolatile salt‐free stabilizer for the quantification of polar imipenem and cilastatin in human plasma using hydrophilic interaction chromatography/quadrupole mass spectrometry with contamination sensitive off‐axis electrospray
A hydrophilic interaction chromatography/mass spectrometry (HILIC‐MS)‐based assay for imipenem (IMP) and cilastatin (CIL) was recently reported. This orthogonal electrospray ion source‐based (ORS) assay utilized nonvolatile salt (unremovable) to stabilize IMI in plasma. Unfortunately, this method was not applicable to conventional MS with off‐axis spray (OAS‐MS) because MS sensitivity was rapidly deteriorated by the nonvolatile salt. Therefore, we aimed to find a nonvolatile salt‐ and ion suppression‐free approach to stabilize and measure the analytes in plasma using OAS‐MS. Acetonitrile and methanol were tested to stabilize the analytes in the plasma samples. The recoveries, matrix effects and stabilities of the analytes in the stabilizer‐treated samples were studied. The variations in MS signal intensities were used as the indicator of the assay ruggedness. The results show that a mixture of methanol and acetonitrile (1:1) is best for the storage and measurement of IMP and CIL in human plasma. Utilization of this precipitant not only blocked the hydrolysis of the analytes in plasma but also resulted in an ion suppression‐free, fast (120 s per sample) and sensitive detection. The sensitivity obtained using the less sensitive OAS‐MS (API3000, 4 pg on column) is much greater than that of the published ORS‐MS‐based assay (API4000, 77 pg on column). The ruggedness of the assay was demonstrated by its constant MS signal intensity. In conclusion, an improved HILIC/MS‐based assay for IMP and CIL was established. The approach presented here provides a simple solution to the challenge of analyzing hydrolytically unstable β‐lactam antibiotics in biological samples. Copyright © 2013 John Wiley & Sons, Ltd.
- 15 March 2013
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 52 (6) , 433-441
Disposition Pathway-Dependent Approach for Predicting Organic Anion-Transporting Polypeptide-Mediated Drug–Drug Interactions
Organic anion-transporting polypeptide (OATP)-mediated drug–drug interactions (DDIs) are among the most important classes of clinically relevant DDIs. Accurate prediction of the OATP-mediated DDIs is not successful due to the sequential disposition pathways of OATP substrates in humans. Intestinal and hepatic uptake transporters, efflux transporters, and cytochrome P450 (CYP) enzymes are often involved in the sequential disposition pathways of typical OATP substrates. The aim of this proof-of-concept study is to develop and validate a novel approach which can be used to predict OATP-mediated DDIs with significantly increased accuracy and decreased false-negatives.
- 15 March 2013
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 52 (6) , 433-441
Disposition Pathway-Dependent Approach for Predicting Organic Anion-Transporting Polypeptide-Mediated Drug–Drug Interactions
Organic anion-transporting polypeptide (OATP)-mediated drug–drug interactions (DDIs) are among the most important classes of clinically relevant DDIs. Accurate prediction of the OATP-mediated DDIs is not successful due to the sequential disposition pathways of OATP substrates in humans. Intestinal and hepatic uptake transporters, efflux transporters, and cytochrome P450 (CYP) enzymes are often involved in the sequential disposition pathways of typical OATP substrates. The aim of this proof-of-concept study is to develop and validate a novel approach which can be used to predict OATP-mediated DDIs with significantly increased accuracy and decreased false-negatives.
- 4 September 2012
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 72, 245-250
Simple and sensitive assay for quantification of oseltamivir and its active metabolite oseltamivir carboxylate in human plasma using high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry: Improved applicability to pharmacokinetic study
- 4 September 2012
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 72, 245-250
Simple and sensitive assay for quantification of oseltamivir and its active metabolite oseltamivir carboxylate in human plasma using high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry: Improved applicability to pharmacokinetic study
- 1 August 2012
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 40 (8) , 1487-1494
In Vivo Information-Guided Prediction Approach for Assessing the Risks of Drug-Drug Interactions Associated with Circulating Inhibitory Metabolites
The in vivo drug-drug interaction (DDI) risks associated with cytochrome P450 inhibitors that have circulating inhibitory metabolites cannot be accurately predicted by conventional in vitro-based methods. A novel approach, in vivo information-guided prediction (IVIP), was recently introduced for CYP3A- and CYP2D6-mediated DDIs. This technique should be applicable to the prediction of DDIs involving other important cytochrome P450 metabolic pathways. Therefore, the aims of this study were to extend the IVIP approach to CYP2C9-mediated DDIs and evaluate the IVIP approach for predicting DDIs associated with inhibitory metabolites. The analysis was based on data from reported DDIs in the literature. The IVIP approach was modified and extended to CYP2C9-mediated DDIs. Thereafter, the IVIP approach was evaluated for predicting the DDI risks of various inhibitors with inhibitory metabolites. Although the data on CYP2C9-mediated DDIs were limited compared with those for CYP3A- and CYP2D6-mediated DDIs, the modified IVIP approach successfully predicted CYP2C9-mediated DDIs. For the external validation set, the prediction accuracy for area under the plasma concentration-time curve (AUC) ratios ranged from 70 to 125%. The accuracy (75–128%) of the IVIP approach in predicting DDI risks of inhibitors with circulating inhibitory metabolites was more accurate than in vitro-based methods (28–805%). The IVIP model accommodates important confounding factors in the prediction of DDIs, which are difficult to handle using in vitro-based methods. In conclusion, the IVIP approach could be used to predict CYP2C9-mediated DDIs and is easily modified to incorporate the additive effect of circulating inhibitory metabolites.
- 1 August 2012
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 40 (8) , 1487-1494
In Vivo Information-Guided Prediction Approach for Assessing the Risks of Drug-Drug Interactions Associated with Circulating Inhibitory Metabolites
The in vivo drug-drug interaction (DDI) risks associated with cytochrome P450 inhibitors that have circulating inhibitory metabolites cannot be accurately predicted by conventional in vitro-based methods. A novel approach, in vivo information-guided prediction (IVIP), was recently introduced for CYP3A- and CYP2D6-mediated DDIs. This technique should be applicable to the prediction of DDIs involving other important cytochrome P450 metabolic pathways. Therefore, the aims of this study were to extend the IVIP approach to CYP2C9-mediated DDIs and evaluate the IVIP approach for predicting DDIs associated with inhibitory metabolites. The analysis was based on data from reported DDIs in the literature. The IVIP approach was modified and extended to CYP2C9-mediated DDIs. Thereafter, the IVIP approach was evaluated for predicting the DDI risks of various inhibitors with inhibitory metabolites. Although the data on CYP2C9-mediated DDIs were limited compared with those for CYP3A- and CYP2D6-mediated DDIs, the modified IVIP approach successfully predicted CYP2C9-mediated DDIs. For the external validation set, the prediction accuracy for area under the plasma concentration-time curve (AUC) ratios ranged from 70 to 125%. The accuracy (75–128%) of the IVIP approach in predicting DDI risks of inhibitors with circulating inhibitory metabolites was more accurate than in vitro-based methods (28–805%). The IVIP model accommodates important confounding factors in the prediction of DDIs, which are difficult to handle using in vitro-based methods. In conclusion, the IVIP approach could be used to predict CYP2C9-mediated DDIs and is easily modified to incorporate the additive effect of circulating inhibitory metabolites.